aspirin placebo (ASA Pbo) — Competitive Intelligence Brief

aspirin placebo (ASA Pbo) (aspirin placebo (ASA Pbo)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Cardiovascular.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2 Cardiovascular Small molecule

Target snapshot

aspirin placebo (ASA Pbo) (aspirin placebo (ASA Pbo)) — Abbott. Aspirin works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins and thromboxanes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
aspirin placebo (ASA Pbo) TARGET	aspirin placebo (ASA Pbo)	Abbott	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Tylenol and Ibuprofen only	Tylenol and Ibuprofen only	The Cooper Health System	marketed	Analgesic/Antipyretic combination (acetaminophen + NSAID)	Prostaglandin synthesis pathway; COX-1 and COX-2 enzymes
alpha-blocker and NSAID	alpha-blocker and NSAID	Samsung Medical Center	marketed	Alpha-blocker and NSAID combination	Alpha-1 adrenergic receptor; COX-1 and COX-2 enzymes
Ropivacaine, Ketorolac and Adrenaline	Ropivacaine, Ketorolac and Adrenaline	University of Aarhus	marketed	Local anesthetic combination with NSAID and vasopressor	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline)
DICL-SR	DICL-SR	Kunming Baker Norton Pharmaceutical Sales Co., Ltd.	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2
Non-selective NSAIDS	Non-selective NSAIDS	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Non-selective NSAID	COX-1 and COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class